Evidence map›Paper›PMID 29166921›Full record

ArticleJournal of nanobiotechnology2017

Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.

Huai-Lu Chen, Fei-Ting Hsu, Yu-Chieh Jill Kao, Hua-Shan Liu, Wan-Zhen Huang, Chia-Feng Lu, Ping-Huei Tsai, Ahmed Atef Ahmed Ali, Gilbert Aaron Lee, Ray-Jade Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Huai-Lu ChenTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Fei-Ting HsuTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Yu-Chieh Jill KaoTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Hua-Shan LiuTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Wan-Zhen HuangDepartment of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
Chia-Feng LuTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ping-Huei TsaiTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ahmed Atef Ahmed AliTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Gilbert Aaron LeeTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ray-Jade ChenDepartment of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. rayjchen@tmu.edu.tw.
Cheng-Yu ChenTranslational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan. sandy0932@gmail.com.
Taipei Medical University · TWTaipei Medical University Hospital · TWNational Yang Ming University Hospital · TW

Funding

Health and welfare surcharge of tobacco products grant MOHW106-TDU-B-212-144001Taipei Medical University Hospital 105TMUH-SP-01Taipei Medical University Hospital 105TMUH-SP-03
6 · The paper itself

Abstract

backgroundTargeted superparamagnetic iron oxide (SPIO) nanoparticles have emerged as a promising biomarker detection tool for molecular magnetic resonance (MR) image diagnosis. To identify patients who could benefit from Epidermal growth factor receptor (EGFR)-targeted therapies, we introduce lipid-encapsulated SPIO nanoparticles and hypothesized that anti-EGFR antibody cetuximab conjugated of such nanoparticles can be used to identify EGFR-positive glioblastomas in non-invasive T

resultsThe synthesized targeted EGFR-antibody-conjugated SPIO (EGFR-SPIO) nanoparticles were characterized using dynamic light scattering, zeta potential assays, gel electrophoresis mobility shift assays, transmission electron microscopy (TEM) images, and cell line affinity assays, and the results showed that the conjugation was successful. The targeting efficiency of the synthesized EGFR-SPIO nanoparticles was confirmed through Prussian blue staining and TEM images by using glioblastoma cell lines with high or low EGFR expression levels. The EGFR-SPIO nanoparticles preferentially targeted U-251 cells, which have high EGFR expression, and were internalized by cells in a prolonged incubation condition. Moreover, the T

conclusionThese findings reveal that the lipid-encapsulated EGFR-SPIO nanoparticles can specifically target cells with elevated EGFR expression in the three tested human glioblastoma cell lines. The results of this study can be used for noninvasive molecular MR image diagnosis in the future.

Indexed as

Antineoplastic Agents, ImmunologicalBiomarkers, TumorCell Line, TumorCetuximabDrug CompoundingErbB ReceptorsGene ExpressionHumansImmunoconjugatesLigandsLipidsMagnetic Resonance ImagingMagnetite NanoparticlesNeurogliaProtein BindingAntineoplastic Agents, ImmunologicalBiomarkers, TumorCetuximabEGFR protein, humanErbB ReceptorsImmunoconjugatesLigandsLipidsMagnetite NanoparticlesEpidermal growth factor receptor (EGFR)GlioblastomaLipid-encapsulated nanoparticleMagnetic resonance imaging (MRI)Targeted superparamagnetic iron oxide (SPIO) nanoparticle

Identifiers

PMID29166921
PMCPMC5700523
OpenAlexW2770705864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.